Elicio Therapeutics (ELTX) Operating Expenses (2020 - 2026)

Elicio Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 1.25% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $37.6 million (down 17.37% YoY), and the FY2025 full-year result was $37.7 million, down 16.17% from the prior year.
• Operating Expenses for Q1 2026 stood at $10.6 million, up from $8.8 million in the prior quarter.
• The five-year high for Operating Expenses was $16.1 million in Q1 2022, with the low at $5.8 million in Q3 2022.
• Historically, Operating Expenses has averaged $9.6 million across 5 years, with a median of $10.1 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Expenses slumped 66.82% — and 2023, when it soared 86.67%.
• Elicio Therapeutics' Operating Expenses stood at $6.0 million in 2022, then jumped by 57.56% to $9.4 million in 2023, then soared by 43.48% to $13.5 million in 2024, then sank by 34.39% to $8.8 million in 2025, then climbed by 19.9% to $10.6 million in 2026.
• The last three Operating Expenses figures came in at $10.6 million (Q1 2026), $8.8 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.